Patrick L Fitzgibbons

Summary

Publications

  1. ncbi Are there barriers to the release of paraffin blocks for clinical research trials? A College of American Pathologists survey of 609 laboratories
    Patrick L Fitzgibbons
    Department of Pathology, St Jude Medical Center, Fullerton, California 92835, USA
    Arch Pathol Lab Med 135:870-3. 2011
  2. ncbi Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays
    Patrick L Fitzgibbons
    Department of Pathology, St Jude Medical Center, Fullerton, California 92835, USA
    Arch Pathol Lab Med 134:930-5. 2010
  3. ncbi Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey
    Patrick L Fitzgibbons
    Department of Pathology, St Jude Medical Center, Fullerton, Calif, USA
    Arch Pathol Lab Med 130:1440-5. 2006
  4. ncbi Laboratory compliance with the American Society of Clinical Oncology/college of American Pathologists guidelines for human epidermal growth factor receptor 2 testing: a College of American Pathologists survey of 757 laboratories
    Raouf E Nakhleh
    Department of Pathology, Mayo Clinic Florida, Jacksonville, FL 32224, USA
    Arch Pathol Lab Med 134:728-34. 2010
  5. ncbi Immunohistochemistry validation procedures and practices: a College of American Pathologists survey of 727 laboratories
    Lindsay B Hardy
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Arch Pathol Lab Med 137:19-25. 2013
  6. ncbi Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast
    Yunn Yi Chen
    Department of Pathology, University of California San Francisco, California 94143, USA
    Am J Surg Pathol 33:1683-94. 2009
  7. ncbi The CD117 immunohistochemistry tissue microarray survey for quality assurance and interlaboratory comparison: a College of American Pathologists Cell Markers Committee Study
    David M Dorfman
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Arch Pathol Lab Med 130:779-82. 2006
  8. ncbi Consensus statement on effective communication of urgent diagnoses and significant, unexpected diagnoses in surgical pathology and cytopathology from the College of American Pathologists and Association of Directors of Anatomic and Surgical Pathology
    Raouf E Nakhleh
    Department of Pathology, Mayo Clinic Florida, Jacksonville, 32224, USA
    Arch Pathol Lab Med 136:148-54. 2012
  9. ncbi Protocol for the examination of specimens from patients with primary carcinomas of the colon and rectum
    Mary Kay Washington
    Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232-2561, USA
    Arch Pathol Lab Med 132:1182-93. 2008
  10. ncbi Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training
    Roderick R Turner
    Department of Pathology, Saint John s Health Center, 1328 Twenty Second St, Santa Monica, CA 90404, USA
    J Clin Oncol 26:258-63. 2008

Collaborators

Detail Information

Publications10

  1. ncbi Are there barriers to the release of paraffin blocks for clinical research trials? A College of American Pathologists survey of 609 laboratories
    Patrick L Fitzgibbons
    Department of Pathology, St Jude Medical Center, Fullerton, California 92835, USA
    Arch Pathol Lab Med 135:870-3. 2011
    ..The number of paraffin blocks submitted for patients enrolled in clinical research trials appears to be declining...
  2. ncbi Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays
    Patrick L Fitzgibbons
    Department of Pathology, St Jude Medical Center, Fullerton, California 92835, USA
    Arch Pathol Lab Med 134:930-5. 2010
    ....
  3. ncbi Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey
    Patrick L Fitzgibbons
    Department of Pathology, St Jude Medical Center, Fullerton, Calif, USA
    Arch Pathol Lab Med 130:1440-5. 2006
    ..Cores found to be IHC-positive or IHC-negative by participant consensus can be used as validated benchmarks for interlaboratory comparison, allowing laboratories to assess their performance and determine if improvements are needed...
  4. ncbi Laboratory compliance with the American Society of Clinical Oncology/college of American Pathologists guidelines for human epidermal growth factor receptor 2 testing: a College of American Pathologists survey of 757 laboratories
    Raouf E Nakhleh
    Department of Pathology, Mayo Clinic Florida, Jacksonville, FL 32224, USA
    Arch Pathol Lab Med 134:728-34. 2010
    ..To ensure quality human epidermal growth receptor 2 (HER2) testing in breast cancer, the American Society of Clinical Oncology/College of American Pathologists guidelines were introduced with expected compliance by 2008...
  5. ncbi Immunohistochemistry validation procedures and practices: a College of American Pathologists survey of 727 laboratories
    Lindsay B Hardy
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Arch Pathol Lab Med 137:19-25. 2013
    ..The immunohistochemistry (IHC) laboratory represents a dynamic area of surgical pathology with limited practice guidelines. Studies have shown significant interlaboratory variability in results...
  6. ncbi Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast
    Yunn Yi Chen
    Department of Pathology, University of California San Francisco, California 94143, USA
    Am J Surg Pathol 33:1683-94. 2009
    ..However, clinical follow-up studies will be required to define the natural history and most appropriate management of these lesions...
  7. ncbi The CD117 immunohistochemistry tissue microarray survey for quality assurance and interlaboratory comparison: a College of American Pathologists Cell Markers Committee Study
    David M Dorfman
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Arch Pathol Lab Med 130:779-82. 2006
    ..Consequently, correct identification of c-Kit expression is important for the diagnosis and treatment of GISTs...
  8. ncbi Consensus statement on effective communication of urgent diagnoses and significant, unexpected diagnoses in surgical pathology and cytopathology from the College of American Pathologists and Association of Directors of Anatomic and Surgical Pathology
    Raouf E Nakhleh
    Department of Pathology, Mayo Clinic Florida, Jacksonville, 32224, USA
    Arch Pathol Lab Med 136:148-54. 2012
    ....
  9. ncbi Protocol for the examination of specimens from patients with primary carcinomas of the colon and rectum
    Mary Kay Washington
    Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232-2561, USA
    Arch Pathol Lab Med 132:1182-93. 2008
  10. ncbi Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training
    Roderick R Turner
    Department of Pathology, Saint John s Health Center, 1328 Twenty Second St, Santa Monica, CA 90404, USA
    J Clin Oncol 26:258-63. 2008
    ..We sought to determine whether a set of clearly defined histologic criteria could lead to reproducible nodal classification by pathologists...